Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

2.815 -0.005 (-0.18%)

Streaming Delayed Price Updated: 10:50 AM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday ↗

November 12, 2024

Via Benzinga

This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

November 12, 2024

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

MarketBeat Week in Review – 11/4 - 11/8

November 09, 2024

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

Via MarketBeat

Topics Economy Government

Decoding 4 Analyst Evaluations For Altimmune ↗

August 22, 2024

Via Benzinga

ALT Stock Earnings: Altimmune Misses EPS for Q2 2024 ↗

August 08, 2024

ALT stock results show that Altimmune missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

How Altimmune Could Grab a Big Chunk of the GLP-1 Market

November 08, 2024

Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.

Via MarketBeat

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) ↗

September 17, 2024

Telemedicine once seemed like it was going to revolutionize healthcare.

Via The Motley Fool

3 Promising Biotech Stocks for the Long-Term: August 2024 ↗

August 13, 2024

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.

Via InvestorPlace

The 7 Best Under $10 Stocks to Buy in August 2024 ↗

August 11, 2024

Buying low-priced stocks carries risk, but lower interest rates may lower the risk premium on these best stocks under $10.

Via InvestorPlace

Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year ↗

August 09, 2024

Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.

Via The Motley Fool

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

August 07, 2024

From CytoSorbents

Via GlobeNewswire

Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now. ↗

August 02, 2024

Via The Motley Fool

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 30, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? ↗

July 20, 2024

At least one of the pair has a credible shot at finding a home in the market.

Via The Motley Fool

3 Undervalued Biotech Stocks With Breakout Potential ↗

July 19, 2024

Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements

Via InvestorPlace

Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio ↗

July 17, 2024

These three wild-card stocks will spice up your portfolio in ways boring diversification never could, so read on.

Via InvestorPlace

Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics ↗

July 10, 2024

Both competitors have promising lead programs, and enough cash, too.

Via The Motley Fool

Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug

July 09, 2024

Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been

Via MarketBeat

7 Bullish Stock Picks With the Potential to Turn $5K Into $50K ↗

July 09, 2024

These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases.

Via InvestorPlace

The 7 Best Under $10 Stocks to Buy in July 2024 ↗

July 06, 2024

We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.

Via InvestorPlace

MarketBeat Week in Review – 7/1 - 7/5

July 06, 2024

The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season

Via MarketBeat

Topics Economy

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, Harbor Diversified, Altimmune, and Sprout Social and Encourages Investors to Contact the Firm

July 04, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

July 04, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm

July 03, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)

July 03, 2024

From Law Offices of Frank R. Cruz

Via Business Wire

Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?

July 03, 2024

Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases

Via MarketBeat

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

July 02, 2024

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Altimmune, Inc. - Common Stock (NQ:ALT)

All News about Altimmune, Inc. - Common Stock